[HTML] springer.comFull View

[HTML][HTML] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg… - BMC cancer, 2019 - Springer
Background A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …
被引用次数：76 相关文章
[PDF] researchgate.net

[PDF][PDF] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg… - 2019 - researchgate.net
Background: A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …
[PDF] helsinki.fi

[PDF][PDF] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naive glioblastoma

E Skaga - 2019 - researchportal.helsinki.fi
Background: A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …

[引用][C] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg… - BMC Cancer, 2019 - cir.nii.ac.jp

[引用][C] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naive glioblastoma

E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg… - 2019 - julkari.fi
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naive glioblastoma
Hyppää sisältöön Näytä/piilota sivun navigointi Näytä/piilota sivun navigointi Näytä viite Etusivu …
[PDF] helsinki.fi

[PDF][PDF] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg… - 2019 - helda.helsinki.fi
Background: A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

E Skaga, E Kulesskiy, A Fayzullin… - BMC …, 2019 - pubmed.ncbi.nlm.nih.gov
Background A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …
[HTML] biomedcentral.com

[HTML][HTML] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

E Skaga, E Kulesskiy, A Fayzullin… - BMC …, 2019 - bmccancer.biomedcentral.com
A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral
heterogeneity at the genetic and cellular level. In early phase clinical trials, patient …
[HTML] nih.gov

[HTML][HTML] Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg… - BMC Cancer, 2019 - ncbi.nlm.nih.gov
Background A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

E Skaga, E Kulesskiy, A Fayzullin… - Skaga, Erlend (2021) …, 2019 - duo.uio.no
Background A major barrier to effective treatment of glioblastoma (GBM) is the large
intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials …